Fulcrum Therapeutics to Participate in Upcoming September Conferences
Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company, has announced its participation in two upcoming healthcare conferences in September 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company, has announced its participation in two upcoming healthcare conferences in September 2024. The company, which focuses on developing small molecules for genetically defined rare diseases, will be attending:
1. The Wells Fargo Healthcare Conference on Wednesday, September 4, 2024, in Boston, MA.
2. The Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6, 2024, in New York, NY.
During these events, Fulcrum's management team will engage in a series of investor meetings, providing an opportunity to discuss the company's progress and future plans in the field of rare disease treatments.
Details
News Market Reaction – FULC
The recorded move for FULC in the trading session of this news was +0.17%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a series of investor meetings at the following conferences:
- Wells Fargo Healthcare Conference
Wednesday, September 4, 2024
Boston, MA
- Morgan Stanley 22nd Annual Global Healthcare Conference
Friday, September 6, 2024
New York, NY
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Contact:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.